ArticleGland surgery2026
Efficacy of dual-modality ablation for symptomatic cystic thyroid nodules.
Article in Gland surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Radiofrequency ablation (RFA) and ethanol ablation (EA) are the most widely used percutaneous treatment modalities for cystic thyroid nodules. We examined outcomes of combined RFA and EA. Methods: We retrospectively analyzed data from 15 patients who underwent concurrent RFA and EA for treatment of cystic thyroid nodules. Patient factors and cyst characteristics were assessed to measure efficacy. The primary outcome was the volume reduction rate and complete resolution of cystic nodule. Secondary outcomes were the incidence of post-procedural complications. Results: The mean age of the patients was 61.3±17.3 years, with females comprising 60%. The median cyst volume decreased substantially from 9.93 mL [interquartile range (IQR), 1.9-40.5 mL] to 1.3 mL (IQR, 0.23-6.35 mL) following RFA/EA treatment. The median volume reduction ratio (VRR) at the last follow-up was 87% (IQR, 50-97%). Complete resolution of the cyst and recurrence were observed in one patient each. No progression of the cyst was reported. Post-procedural complications were minimal, and all post-procedural discomfort resolved within 2 weeks. Conclusions: RFA and EA are effective, percutaneous treatment options for cystic thyroid nodules when used independently, but the combined usage showed substantial volume reduction comparable to previously reported outcomes of monotherapy. All patients achieved symptomatic resolution with minimal post-procedural complications. Larger studies are needed to optimize treatment protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.